Cathal O'Leary1, Mary Mahler2, Michael C Soulen3. 1. Department of Radiology, 3400 Spruce St, Philadelphia, PA, 19104, USA. 2. University of Toronto, 500 University Avenue, Suite 602, Toronto, Ontario, M5G1V7, Canada. 3. Department of Radiology, 3400 Spruce St, Philadelphia, PA, 19104, USA. michael.soulen@pennmedicine.upenn.edu.
Abstract
PURPOSE OF REVIEW: The high mortality rate for hepatocellular carcinoma (HCC) relative to its prevalence underscores the need for curative-intent therapies. Image-guided therapies such as ablation and embolization have an established role as primary or neoadjuvants preparing patients for curative treatment. RECENT FINDINGS: For HCC < 3 cm, percutaneous thermal ablation provides oncologic outcomes similar to surgical resection and is now a recommended first-line therapy in the EASL guidelines. Both ablation and embolization are recommended as bridging therapies for HCC patients awaiting liver transplantation. T3 HCC can be downstaged by embolization to T2, allowing liver transplantation with similar outcomes to patients transplanted within Milan criteria. New and evolving techniques such as SBRT, radiation segmentectomy and lobectomy, and combination therapies show promise but require further prospective data before they can be integrated into treatment algorithms. Combinations of embolic, ablative, and extirpative therapies can increase access to curative-intent treatment of HCC. Multidisciplinary treatment decisions are required to craft optimal treatment strategies considering tumor size, location, and underlying liver cirrhosis.
PURPOSE OF REVIEW: The high mortality rate for hepatocellular carcinoma (HCC) relative to its prevalence underscores the need for curative-intent therapies. Image-guided therapies such as ablation and embolization have an established role as primary or neoadjuvants preparing patients for curative treatment. RECENT FINDINGS: For HCC < 3 cm, percutaneous thermal ablation provides oncologic outcomes similar to surgical resection and is now a recommended first-line therapy in the EASL guidelines. Both ablation and embolization are recommended as bridging therapies for HCCpatients awaiting liver transplantation. T3 HCC can be downstaged by embolization to T2, allowing liver transplantation with similar outcomes to patients transplanted within Milan criteria. New and evolving techniques such as SBRT, radiation segmentectomy and lobectomy, and combination therapies show promise but require further prospective data before they can be integrated into treatment algorithms. Combinations of embolic, ablative, and extirpative therapies can increase access to curative-intent treatment of HCC. Multidisciplinary treatment decisions are required to craft optimal treatment strategies considering tumor size, location, and underlying liver cirrhosis.
Authors: Jorge A Marrero; Laura M Kulik; Claude B Sirlin; Andrew X Zhu; Richard S Finn; Michael M Abecassis; Lewis R Roberts; Julie K Heimbach Journal: Hepatology Date: 2018-08 Impact factor: 17.425
Authors: David A Bush; Jason C Smith; Jerry D Slater; Michael L Volk; Mark E Reeves; Jason Cheng; Roger Grove; Michael E de Vera Journal: Int J Radiat Oncol Biol Phys Date: 2016-02-13 Impact factor: 7.038
Authors: V Mazzaferro; E Regalia; R Doci; S Andreola; A Pulvirenti; F Bozzetti; F Montalto; M Ammatuna; A Morabito; L Gennari Journal: N Engl J Med Date: 1996-03-14 Impact factor: 176.079
Authors: Cynthia De la Garza-Ramos; Cameron J Overfield; S Ali Montazeri; Harris Liou; Ricardo Paz-Fumagalli; Gregory T Frey; J Mark McKinney; Charles A Ritchie; Zlatko Devcic; Andrew R Lewis; Denise M Harnois; Tushar Patel; Beau B Toskich Journal: J Hepatocell Carcinoma Date: 2021-07-30